Palisade Bio reported a second-quarter net loss of $10.6 million, up from $2.8 million a year earlier, while loss per share narrowed to $0.05 from $0.58. The company recorded $0.5 million in licensing revenue from a milestone payment under a distribution agreement with Newsoara, a joint venture established by Biolead Medical Technology Limited. Cash and equivalents stood at $125.2 million as of June 30, 2026, expected to fund operations into early 2028. The Phase 2 ASCENTRA-UC trial of lead candidate PALI-2108 for ulcerative colitis is planned to begin enrollment in the second half of 2026, with primary efficacy data anticipated in the second half of 2027. For Crohn’s disease, an IND submission for the ASCENTRA-CD study is expected in the second half of 2026, with trial commencement in the first quarter of 2027 and primary efficacy readout in early 2028. Shares fell 3.33% in overnight trading to $2.03.
Palisade Bio IncQ2 net loss widened to $10.6 million from $2.8 million, though loss per share narrowed.
